104 reports of this reaction
1.5% of all ROPIVACAINE HYDROCHLORIDE reports
#15 most reported adverse reaction
NASAL OEDEMA is the #15 most commonly reported adverse reaction for ROPIVACAINE HYDROCHLORIDE, manufactured by Fresenius Kabi USA, LLC. There are 104 FDA adverse event reports linking ROPIVACAINE HYDROCHLORIDE to NASAL OEDEMA. This represents approximately 1.5% of all 6,839 adverse event reports for this drug.
Patients taking ROPIVACAINE HYDROCHLORIDE who experience nasal oedema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NASAL OEDEMA is a less commonly reported adverse event for ROPIVACAINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to nasal oedema, the following adverse reactions have been reported for ROPIVACAINE HYDROCHLORIDE:
The following drugs have also been linked to nasal oedema in FDA adverse event reports:
NASAL OEDEMA has been reported as an adverse event in 104 FDA reports for ROPIVACAINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NASAL OEDEMA accounts for approximately 1.5% of all adverse event reports for ROPIVACAINE HYDROCHLORIDE, making it a notable side effect.
If you experience nasal oedema while taking ROPIVACAINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.